https://register.epo.org/application?number=EP17783057
Ultragenyx Reports Preliminary 2023 Revenue; Guidance For 2024 Revenue And Cash Usage; Pipeline Updates And 2024 Milestones; Sees FY23 Revenue $430-$435M Vs $435.9M Est.; Sees FY24 Revenue $500M-$530M Vs $523.86M Est.; Year-End 2023 Cash Balance Of ~$7…
Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million2024 expected Total Revenue guidance
